NS Pharma, Inc.
This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.
Inclusion Criteria 1. Participant has successfully completed Study NS-089/NCNP-02-201 2. Participant and parent(s) or legal guardian(s) are willing and able to comply with scheduled visits, investigational product (IP) administration plan, and study procedures 3. Participant must be on a stable dose of glucocorticoid (GC) steroids and is expected to remain on a stable dose of GC steroid treatment for the duration of the study 4. Other inclusion criteria may apply Exclusion Criteria: 1. Participant had an adverse event (AE) in Study NS-089/NCNP-02-201 that, in the judgment of the investigato…
Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.